Home
News
Topics
Sectors
Reports
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Project Updates and Milestones news
(page 2)
5 March 2026
RWE Adds 2 GW to U.S. Energy Capacity
RWE completed 15 projects in 2025, adding solar, wind, and battery storage across seven U.S. states, creating 3,500 jobs and investing over $500 million in local communities.
4 March 2026
thyssenkrupp Uhde Installs EnviNOx® for Emission Cuts at CSBP Nitric Acid Plants
EnviNOx® tech cuts N₂O emissions by 98% at CSBP's NAAN3 plant, aiding WesCEF's 2030 emission goals and supporting decarbonization in agriculture and mining.
4 March 2026
Topsoe's 2025 Financial Results Meet Expectations in Tough Market
Revenue reached DKK 8,197 million. EBIT margin at 8.9%. SAF projects in China. New CEO from March 2026. 2026 outlook: revenue DKK 7,600-8,400 million, EBIT margin 0.0-5.0%.
4 March 2026
thyssenkrupp Uhde's EnviNOx® Cuts Nitrous Oxide Emissions at CSBP
EnviNOx® tech reduces N₂O emissions by 98% at CSBP's nitric acid plants, aiding WesCEF's 2030 emissions goals and supporting decarbonization in agriculture and mining.
4 March 2026
NEXTCHEM Secures €485M Contract for Hydrogen, Ammonia, Urea, and Methanol Technologies in West Africa
The project includes hydrogen, ammonia, and urea units across three sites. Engineering has begun, with €10M recognized pre-FID.
4 March 2026
Sinopec Backs New National Greenhouse Gas Emission Database
The updated database includes methane emission factors for onshore facilities, aiding accurate greenhouse gas calculations and supporting emission reduction efforts in the oil and gas sector.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
3 March 2026
Johnson & Johnson's Nipocalimab Gets FDA Fast Track for Lupus Treatment
Nipocalimab, an investigational therapy, aims to address unmet needs in lupus by reducing harmful IgG while preserving immune function, following positive Phase 2b results.
3 March 2026
Equinor Investigates Deepsea Bollsta Well Control Incident
A gas leak on Deepsea Bollsta was contained in 30 minutes. Safety systems worked, preventing escalation. Measures are in place to avoid recurrence.
3 March 2026
RIFT Secures €114M to Scale Iron Fuel Technology
€113.8M funding will develop a commercial iron fuel facility, aiming to decarbonize industrial heat and avoid over 1M tonnes of CO₂ emissions. Operational by 2029.
2 March 2026
Takeda's Rusfertide Receives FDA Priority Review
Rusfertide shows promise in controlling hematocrit and reducing symptoms in polycythemia vera, with FDA review based on positive Phase 3 and long-term study data.
2 March 2026
Equinor's Rapid Development Plan for Snorre Oil Discovery
New oil discovery in Snorre area to be quickly developed using existing infrastructure, reducing costs and environmental impact, while supporting European energy security.
2 March 2026
thyssenkrupp Uhde to Study Biomass-to-Methanol Integration for Nova Sustainable Fuels in Canada
The study will assess the integration of gasification and methanol synthesis to produce 450,000 metric tons of bio-methanol annually, aiding decarbonization in transportation and shipping.
2 March 2026
Galp 4Q & FY25 Financial Results
Strong 2025 performance with €2.2bn cash generation, 4% DPS increase, and €250m buyback. Key growth in Brazil, Namibia, and Sines. Net debt at €1.3bn, FCF at €81m.
1 March 2026
Genentech's Fenebrutinib Shows Promise as BTK Inhibitor for MS in Phase III Study
Fenebrutinib reduced relapses by 51% in RMS, consistent with prior studies. Data will be submitted to regulators. Safety profile comparable to teriflunomide; further analysis on fatalities ongoing.
28 February 2026
Merck and Eisai: WELIREG and LENVIMA Reduce Disease Progression Risk by 30% in Advanced RCC Trial
Phase 3 trial shows WELIREG plus LENVIMA improves progression-free survival in advanced RCC, with FDA reviewing new drug applications.
27 February 2026
FDA Approves Novo Nordisk's Sogroya for New Pediatric Uses
Sogroya, a once-weekly growth hormone, is now approved for children with ISS, SGA, or NS, offering an alternative to daily injections and expanding treatment options.
27 February 2026
Merck's KEYTRUDA and Padcev Cut Event-Free Survival Risk by 47% and Mortality by 35% in Cisplatin-Eligible Bladder Cancer Patients
KEYTRUDA plus Padcev improves survival and reduces recurrence in muscle-invasive bladder cancer, showing potential as a new standard for cisplatin-eligible patients.
27 February 2026
Lilly's Olumiant Gains CHMP Nod for Adolescent Alopecia Areata in EU
CHMP backs Olumiant for severe alopecia areata in adolescents, based on Phase 3 study showing 42% achieved 80% scalp hair coverage at 36 weeks. Awaiting European Commission decision.
27 February 2026
KazMunayGas 2025 Trading Update
Hydrocarbon reserves stable; oil and gas production up. Oil transport steady; refining and polypropylene output increased.
27 February 2026
Air Liquide and Holcim Partner to Decarbonize Belgian Cement Production
The agreement aims to capture 1.1 million tons of CO₂ annually at Holcim's Obourg plant, supporting EU's 2050 net zero target through advanced carbon capture and storage technology.
27 February 2026
BASF Advances "Winning Ways" Strategy Milestones
BASF boosts free cash flow, starts Zhanjiang plants, and cuts costs. 2025 EBITDA drops to €6.6B; 2026 outlook: €6.2-7.0B EBITDA, €1.5-2.3B free cash flow.
26 February 2026
GSK's Bepirovirsen Under Review in Japan for Chronic Hepatitis B Treatment
Japan reviews bepirovirsen for chronic hepatitis B. Phase III trials show higher functional cure rates and acceptable safety. SENKU designation granted for expedited review.
26 February 2026
GSK's Linerixibat Gets Priority Review in China for PBC-Related Itch
Linerixibat shows significant improvement in cholestatic pruritus in PBC patients, based on GLISTEN phase III trial data. Regulatory reviews ongoing in US, EU, UK, and Canada.
26 February 2026
PureCycle Technologies Q4 2025 Results and Update
Record production, revenue growth, expansion in Thailand and Belgium, and leadership changes. Gen-2 design shows cost efficiency. Financials stable with ongoing projects and debt management.
26 February 2026
FDA Approves Boehringer Ingelheim's HERNEXEOS for HER2-Mutant NSCLC
HERNEXEOS gains FDA approval for HER2-mutant NSCLC, showing a 76% response rate in trials. Further confirmation required for continued approval.
26 February 2026
Johnson & Johnson Reports Positive Early Results for Pasritamig and Docetaxel in Prostate Cancer
Phase 1b study shows pasritamig and docetaxel combo is safe and effective in prostate cancer, with high PSA response rates, supporting Phase 3 trials.
26 February 2026
Lilly's Orforglipron Outperforms Semaglutide in Diabetes Trial
Orforglipron 36 mg reduced A1C by 2.2% and weight by 9.2%, surpassing semaglutide in a 52-week trial with 1,698 participants. Results published in The Lancet.
26 February 2026
Aramco Advances Gas Expansion with Jafurah and Tanajib Projects
Jafurah and Tanajib projects boost gas production, aiming for 80% capacity increase by 2030, supporting economic growth and energy diversification.
26 February 2026
Eni Reports Strong 2025 Financial and Strategic Progress
Strong Q4 results with 35% net income growth. Major projects launched, production up 7%. LNG expansion, biofuels growth, and strategic partnerships enhance resilience and shareholder returns.
26 February 2026
EEW Advances Flue Gas Cleaning Modernization in Helmstedt
EEW invests in flue gas cleaning to meet strict emissions, enhance environmental performance, and ensure long-term site viability during ongoing operations in Helmstedt.
← Previous
Next →
